跳至主要内容
临床试验/NCT00420134
NCT00420134已完成1 期

A Phase One/Two Clinical Trial on the Use of Autograft Mesenchymal Stem Cells Differentiated Into Progenitor of Hepatocytes for the Salvage Treatment of Patients With End-stage Liver Disease

Shahid Beheshti University of Medical Sciences2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2006年2月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
30
试验地点
2
主要终点
Liver function test

研究概览

简要总结

The methods for separation of mesenchymal stem cell were established in 2001. These cells can differentiate to osteocytes, hepatocytes, chondrocytes, myocytes and etc,. In this study the investigators try to separate mesenchymal stem cell from end stage liver disease, then these cells will be differentiated to progenitor of hepatocytes, finally , the investigators injected these cells into portal vein under ultrasound guide. The investigators determine the effects of injected cells in reestablishment of liver function.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •MELD score of at least 10
  • •Patent portal vein on color Doppler examination of the liver
  • •Normal alpha-feto protein serum levels
  • •Age more than 18
  • •Filling inform consent by patients and first degree family members

排除标准

  • •Any evidence of hepatocellular carcinoma on liver ultrasound studies
  • •Patients want to exclude from study

结局指标

主要结局

Liver function test

MELD score

次要结局

  • Cirrhosis mortality after 6 months

研究者

研究点 (2)

Loading locations...

相似试验